-
1
-
-
0027487314
-
Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain
-
Giudice G.J., Emery D.J., Zelickson B.D., Anhalt G.J., Liu Z., Diaz L.A. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993, 151:5742-5750.
-
(1993)
J Immunol
, vol.151
, pp. 5742-5750
-
-
Giudice, G.J.1
Emery, D.J.2
Zelickson, B.D.3
Anhalt, G.J.4
Liu, Z.5
Diaz, L.A.6
-
2
-
-
0030724110
-
A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid
-
Zillikens D., Mascaro J.M., Rose P.A., Liu Z., Ewing S.M., Caux F., et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997, 109:679-683.
-
(1997)
J Invest Dermatol
, vol.109
, pp. 679-683
-
-
Zillikens, D.1
Mascaro, J.M.2
Rose, P.A.3
Liu, Z.4
Ewing, S.M.5
Caux, F.6
-
3
-
-
0033964612
-
Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid
-
Schmidt E., Obe K., Brocker E.B., Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000, 136:174-178.
-
(2000)
Arch Dermatol
, vol.136
, pp. 174-178
-
-
Schmidt, E.1
Obe, K.2
Brocker, E.B.3
Zillikens, D.4
-
5
-
-
0035034812
-
Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses
-
Laffitte E., Skaria M., Jaunin F., Tamm K., Saurat J.H., Favre B., et al. Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. Br J Dermatol 2001, 144:760-768.
-
(2001)
Br J Dermatol
, vol.144
, pp. 760-768
-
-
Laffitte, E.1
Skaria, M.2
Jaunin, F.3
Tamm, K.4
Saurat, J.H.5
Favre, B.6
-
6
-
-
33846204327
-
Rituximab in autoimmune bullous diseases: mixed responses and adverse effects
-
Schmidt E., Seitz C.S., Benoit S., Brocker E.B., Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007, 156:352-356.
-
(2007)
Br J Dermatol
, vol.156
, pp. 352-356
-
-
Schmidt, E.1
Seitz, C.S.2
Benoit, S.3
Brocker, E.B.4
Goebeler, M.5
-
7
-
-
34547761274
-
A single cycle of rituximab for the treatment of severe pemphigus
-
Joly P., Mouquet H., Roujeau J.C., D'Incan M., Gilbert D., Jacquot S., et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357:545-552.
-
(2007)
N Engl J Med
, vol.357
, pp. 545-552
-
-
Joly, P.1
Mouquet, H.2
Roujeau, J.C.3
D'Incan, M.4
Gilbert, D.5
Jacquot, S.6
-
8
-
-
80051783440
-
Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients
-
Kasperkiewicz M., Shimanovich I., Ludwig R.J., Rose C., Zillikens D., Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011, 65:552-558.
-
(2011)
J Am Acad Dermatol
, vol.65
, pp. 552-558
-
-
Kasperkiewicz, M.1
Shimanovich, I.2
Ludwig, R.J.3
Rose, C.4
Zillikens, D.5
Schmidt, E.6
-
9
-
-
84855352515
-
Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients
-
Khosroshahi A., Carruthers M., Deshpande V., Unizony S., Bloch D., Stone J. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012, 91:57-66.
-
(2012)
Medicine (Baltimore)
, vol.91
, pp. 57-66
-
-
Khosroshahi, A.1
Carruthers, M.2
Deshpande, V.3
Unizony, S.4
Bloch, D.5
Stone, J.6
-
10
-
-
84887822290
-
Association of serum B cell activating factor (BAFF) level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients
-
[advanced online publication 27 June 2013]
-
Hall R.P., Streilein R.D., Hannah D., McNair P., Fairley J.A., Ronaghy A., et al. Association of serum B cell activating factor (BAFF) level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol 2013, [advanced online publication 27 June 2013]. 10.1038/jid.2013.236.
-
(2013)
J Invest Dermatol
-
-
Hall, R.P.1
Streilein, R.D.2
Hannah, D.3
McNair, P.4
Fairley, J.A.5
Ronaghy, A.6
|